Considering promising preclinical data (Table 1) and clinical pilot study results in the GLP-2 analog, teduglutide may have potential to become a new therapeutic option in IBD treatment, showing higher response and remission rates in comparison to placebo (Buchman et al
However, patients on these medications exhibited profound weight-loss, prompting Novo, Lilly, Amgen, and other pharma companies to investigate how these drugs can be used specifically to treat obesity
I could not be happier with her
50 units of semaglutide converts to approximately 1.67 mg, a conversion ratio essential for patients switching between formulations or evaluating different treatment protocols
Diabetologia 49(2):25360 Drucker DJ, Habener JF, Holst JJ (2017) Discovery, characterization, and clinical development of the glucagon-like peptides